Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13644MR)

This product GTTS-WQ13644MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13644MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6700MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ15780MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ1147MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ7570MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ12236MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ14536MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ10525MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2136MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW